“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an ...

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

The stock's fall snapped a three-day winning streak.

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...

Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025.

Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a ...

In a report released today, Michael Matson from Needham reiterated a Buy rating on Stryker (SYK – Research Report), with a price target of ...

Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at ...

Q4 2024 Earnings Call Transcript January 28, 2025 Stryker Corporation beats earnings expectations. Reported EPS is $4.01, expectations were $3.87. Operator: Welcome to the Fourth Quarter 2024 Stryker ...

Stryker is selling its U.S. spinal implant business to investment firm Viscogliosi Brothers, a move that is expected to help the company ...

Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York ...

Medical and surgical device makers are riding on a surge in demand as more people in the U.S., particularly older Americans, ...